Illumina Upgraded to Outperform by SVB Securities
The stock upgrade comes after Illumina launched a new instrument line and chemistry last week and held an investor showcase on Monday.
Prometheus Biosciences Prices Upsized $190M IPO
The company is focused on developing and commercializing therapeutic and companion diagnostic products to treat inflammatory bowel disease.
Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags.
SVB Leerink Initiates Coverage of Twist Bioscience With Market Perform Rating
The synbio company offers scale and lower costs in "massive" end markets, SVB Leerink analysts said, and could soon command an even more attractive valuation.
First Analysis Upgrades NeoGenomics to Strong Buy After Stock Dips
The company's Q4 revenues exceeded Wall Street estimates and the clinical genetic testing and pharma services businesses outperformed expectations.